1 of 1
Story summary
- A trial published in the Annals of Internal Medicine found fluvoxamine reduces fatigue in adults with long COVID, with a 99% probability of outperforming placebo and improving quality of life.
- The trial enrolled 399 participants in Brazil with fatigue for at least 90 days post-infection.
- Metformin showed no meaningful benefits for established long COVID fatigue.
- Researchers call for studies to understand fluvoxamine's mechanisms and role in treating long COVID.
